Target intelligence / Profile preview

Bone

Molecular classification
Other
01

Overview

Bone is a specialized mineralized connective tissue composed of a dense extracellular matrix predominantly consisting of type I collagen and hydroxyapatite crystals, which together provide mechanical strength and rigidity[1][3][7]. It contains four main cell types: osteoblasts (bone-forming), osteocytes (mature, matrix-embedded), osteoclasts (bone-resorbing), and bone lining cells, all coordinating bone remodeling and homeostasis[1][7]. Bone serves structural, protective, metabolic, and hematopoietic functions, and its dynamic remodeling is tightly regulated by local and systemic factors, including various hormones, cytokines, and growth factors[1][7][9]. In clinical medicine, bone is a tissue system rather than a molecular or protein target; therapies for bone diseases commonly target molecular mediators (such as RANKL, parathyroid hormone receptor, sclerostin) or pathways involved in bone cell activity and matrix regulation, rather than "bone" as a discrete target in the sense of a single molecular entity[2][4].

Other names
Bone tissueOsseous tissue
02

Mechanism of action

Bisphosphonates: Inhibit osteoclast-mediated bone resorption Denosumab: RANKL inhibitor, reduces osteoclast formation/function Parathyroid hormone analogs: Intermittent stimulation of bone formation (anabolic effect) Romosozumab: Sclerostin inhibitor, increases bone formation and reduces resorption Calcitonin: Directly inhibits osteoclast activity

03

Biological functions

Mechanical supportMineral storage (especially calcium and phosphate)Hematopoiesis (blood cell formation in bone marrow)Endocrine regulation (via cells and matrix factors)Protection of internal organs
04

Disease associations

OsteoporosisFractureOsteogenesis imperfectaBone cancers (e.g., osteosarcoma, bone metastases)Paget's diseaseOsteomyelitisOther metabolic bone diseases
05

Safety considerations

Osteonecrosis of the jaw (bisphosphonates, denosumab)Atypical femoral fractures (bisphosphonates)Hypercalcemia (parathyroid hormone analogs)Hypocalcemia (denosumab)Increased risk of osteosarcoma (teriparatide, in preclinical models)Cardiovascular risks (romosozumab)General mineral metabolism disturbances
06

Interacting drugs

Bisphosphonates (e.g., alendronate, zoledronic acid)

5 more in the full profile.

07

Biomarkers

Bone mineral density (BMD)Serum calcium and phosphateAlkaline phosphatase (bone-specific isoform)Telopeptides (e.g., CTX, NTX) as markers of bone turnoverOsteocalcinSclerostin

Beyond the preview

Go deeper on Bone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call